Seeking Alpha

Teva faces generic Copaxone a year early

  • Shares of Teva Pharmaceutical (TEVA -2.2%) are lower after the U.S. Court of Appeals invalidates a 2015 Copaxone patent.
  • The company expects the FDA to approve a longer-acting version of the drug early next year and had planned to spend 2014 converting patients to the new dosage. With generic competition now possible in less than a year, TEVA's original plan is now "de facto impossible," according to one hedge fund manager quoted by Bloomberg.
  • Previously: Momenta Pharmaceuticals soars on Copaxone ruling.
Comments (2)
  • doc47
    , contributor
    Comments (994) | Send Message
    Really sick of reading about the mistakes, miscalculations, and pie-in-the-sky "experts'" predictions for this stock. I'm going to greener pastures where management has at least half a brain. Good luck to all.
    29 Jul 2013, 03:22 PM Reply Like
  • bnkd
    , contributor
    Comments (38) | Send Message
    Any credence to Teva saying it is a very complex molecule and difficult to copy copoxone, generic company will have to do clinical
    trial to get FDA approval ?
    29 Jul 2013, 07:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: